Grove Bank & Trust Has $646,000 Holdings in Eli Lilly and Company (LLY)

Grove Bank & Trust raised its stake in Eli Lilly and Company (NYSE:LLY) by 57.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,845 shares of the company’s stock after purchasing an additional 2,850 shares during the quarter. Grove Bank & Trust’s holdings in Eli Lilly and were worth $646,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Bessemer Group Inc. lifted its holdings in shares of Eli Lilly and by 0.5% in the 2nd quarter. Bessemer Group Inc. now owns 3,175,859 shares of the company’s stock valued at $261,374,000 after buying an additional 14,607 shares during the period. CAPROCK Group Inc. lifted its holdings in shares of Eli Lilly and by 114.1% in the 2nd quarter. CAPROCK Group Inc. now owns 9,027 shares of the company’s stock valued at $743,000 after buying an additional 4,811 shares during the period. Lourd Capital LLC lifted its holdings in shares of Eli Lilly and by 6.6% in the 2nd quarter. Lourd Capital LLC now owns 5,883 shares of the company’s stock valued at $484,000 after buying an additional 366 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Eli Lilly and by 12.5% in the 2nd quarter. Tokio Marine Asset Management Co. Ltd. now owns 63,652 shares of the company’s stock valued at $5,239,000 after buying an additional 7,051 shares during the period. Finally, CIBC Asset Management Inc lifted its holdings in shares of Eli Lilly and by 0.3% in the 2nd quarter. CIBC Asset Management Inc now owns 103,852 shares of the company’s stock valued at $8,547,000 after buying an additional 268 shares during the period. Institutional investors own 75.72% of the company’s stock.

Several research firms have recently commented on LLY. BMO Capital Markets reissued a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $93.00 to $90.00 in a report on Wednesday, July 26th. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Finally, UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $88.27.

Eli Lilly and Company (NYSE:LLY) opened at 82.02 on Thursday. The firm’s 50-day moving average price is $80.84 and its 200 day moving average price is $82.02. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market cap of $86.53 billion, a P/E ratio of 35.49 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the firm earned $0.86 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.

WARNING: “Grove Bank & Trust Has $646,000 Holdings in Eli Lilly and Company (LLY)” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/21/grove-bank-trust-has-646000-holdings-in-eli-lilly-and-company-lly.html.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 590,000 shares of company stock valued at $48,551,300 in the last quarter. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply